Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 6/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.33 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316030 | 1.00 | MAPK10 (0.35) | MAPK10BRD4HTTMAPK13MAPK12 | |
| SCHEMBL316031 | 1.00 | MAPK10 (0.35) | MAPK10BRD4HTTMAPK13MAPK12 | |
| SCHEMBL313657 | 0.92 | HSD11B1 (0.41) | BRD4HTTHSD11B1TP53L3MBTL1 | |
| SCHEMBL313656 | 0.92 | HSD11B1 (0.41) | BRD4HTTHSD11B1TP53L3MBTL1 | |
| SCHEMBL313658 | 0.92 | HSD11B1 (0.41) | BRD4HTTHSD11B1TP53L3MBTL1 | |
| SCHEMBL314599 | 0.88 | ALDH1A1 (0.46) | HTTBCHEHSD11B1 | |
| SCHEMBL314597 | 0.88 | ALDH1A1 (0.46) | HTTBCHEHSD11B1 | |
| SCHEMBL314598 | 0.88 | ALDH1A1 (0.46) | HTTBCHEHSD11B1 | |
| SCHEMBL314554 | 0.86 | HSD11B1 (0.46) | BRD4HTTHSD11B1 | |
| SCHEMBL314553 | 0.86 | HSD11B1 (0.46) | BRD4HTTHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | claimed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2007079820-A1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306042-A1 | Triazole Derivatives | TGFBR1, TGFBR2, SMAD3 | MAPK10 1454/4885BRD4 808/4885HTT 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.